Navigation Links
Urologists' Group Issues Updated Guidelines on PSA Test
Date:5/4/2013

FRIDAY, May 3 (HealthDay News) -- New guidelines from the nation's leading group of urologists on the controversial PSA test for prostate cancer highlight the importance of discussions between a man and his doctor.

Especially for men in their late 50s and 60s, the usefulness of the blood test may have to be decided on a case-by-case basis, according to new recommendations from the American Urological Association (AUA).

One expert called the new guidelines "a paradigm shift" in prostate cancer detection.

Dr. Louis Potter, chairman of radiation medicine at North Shore-LIJ Health System in New Hyde Park, N.Y., said the recommendations mark a move to more "personalized health management, where risk and age are balanced against the value of screening."

Prostate-specific antigen (PSA) screening is a test that measures the level of a key marker for prostate cancer in the blood. In general, the higher the level of this protein, the more likely it is that a man has prostate cancer, according to the U.S. National Cancer Institute.

The value of the PSA test has recently come into question, however, with several studies suggesting it causes men more harm than good -- spotting too many slow-growing tumors that, especially in older patients, may never lead to serious illness or death. In 2012, the U.S. Preventive Services Task Force, an influential government-appointed panel, advised against the routine use of the PSA test for prostate cancer.

The new AUA guidelines are more nuanced. The group does recommend against the PSA test for men under age 40 or for those aged 40 to 54 at average risk for prostate cancer.

The AUA says, however, that men aged 55 to 69 should talk to their doctors about the risks and benefits of PSA screening and make a decision based on their personal values and preferences.

Routine PSA screening is not recommended for men over age 70 or any man with less than a 10- to 15-year life expectancy.

The best evidence of benefit from PSA screening was among men aged 55 to 69 screened every two to four years. In this group, PSA testing was found to prevent one death a decade for every 1,000 men screened. But this benefit could be much greater over a lifetime, the guidelines noted.

The guidelines also said PSA screening could benefit men in other age groups who are at higher risk of prostate cancer due to factors such as race and family history. These men should discuss their risk with a doctor and assess the benefits and potential harms of PSA testing.

The new guideline updates the AUA's 2009 Best Practice Statement on Prostate-Specific Antigen and was announced at the association's annual meeting in San Diego on Friday.

"There is general agreement that early detection, including prostate-specific antigen screening, has played a part in decreasing mortality from prostate cancer," Dr. H. Ballentine Carter, who chaired the panel that developed the guidelines, said in an AUA news release.

There is more and better data about PSA screening available today than there was in 2009, so it is "time to reflect on how we screen men for prostate cancer and take a more selective approach in order to maximize benefit and minimize harms," Carter said.

One expert said the revised guidelines made sense.

"I think these guidelines are quite appropriate given the [slow-growing] nature of many prostate cancers," said Dr. Erik Goluboff, an attending urologist in the department of urologic oncology at Beth Israel Medical Center in New York City.

He agreed that discussions between a patient and his doctor on the PSA test are "extremely important."

"It has become increasingly evident that many, if not most, men diagnosed with early prostate cancer will never need treatment and can be spared the potentially devastating side effects of treatment such as urinary incontinence and erectile dysfunction," Goluboff said.

Some men, including black patients and patients with a family history of prostate cancer, may still decide to undergo PSA testing, he added. "This is in contrast to the U.S. Preventive Services Task Force, where a blanket statement that PSA screening is bad, regardless of individual patient risk, was made," Goluboff said.

A better test that pinpoints aggressive, life-threatening prostate tumors might be developed in the future, to better guide patients. "Hopefully, with discovery of better tumor markers, aggressive prostate cancers can be distinguished from [slow-growing] ones and only patients who need to will receive treatment," Goluboff said.

More information

The U.S. National Cancer Institute has more about prostate cancer screening.

-- Robert Preidt

SOURCES: Louis Potters, M.D, chair, radiation medicine, North Shore - LIJ Health System, New Hyde Park, NY; Erik Goluboff, M.D., attending urologist, department of urologic oncology, Beth Israel Medical Center, New York City; American Urological Association, news release, May 3, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
2. Specialist urologists should handle vasectomy reversal cases says 10-year study
3. Hospital-based neurologists worry about career burnout
4. Alzheimers Patients May Face Looming Shortage of Neurologists
5. Physician Groups Call for Fewer Medical Tests
6. From herd immunity and complacency to group panic: How vaccine scares unfold
7. Study finds significant skull differences between closely linked groups
8. Diabetes Groups Issue New Guidelines on Blood Sugar
9. Small neural focus groups predict anti-smoking ad success
10. Group B streptococcal meningitis has long-term effects on childrens developmental outcomes
11. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Urologists' Group Issues Updated Guidelines on PSA Test
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and ... the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for ... Forum and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, ...
(Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... DPLO ) is pleased to announce the promotion of Paul Urick to Senior Vice ... To learn more about our Diplomat executive team, click ... ... ... In his redefined role at Diplomat, Urick ...
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, ... conference call and webcast to discuss its financial results ... 2015, on Thursday, February 25, 2016 at 8:00 a.m. ... prior to the conference call and webcast.  On the ... financial results, highlights from the fourth quarter and business ...
(Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
Breaking Medicine Technology: